2024-11-11 09:04Financial Performance - Core product Orelabrutinib (Yinokai®) achieved sales revenue of CNY 276 million in Q3 2024, a year-on-year increase of 75.5%[2] - Total revenue for the first nine months of 2024 reached CNY 698 million, representing a growth of 29.8% compared to the same period last year[4] - Gross profit margin for the first nine months of 2024 was 86.0%, up 4.8 percentage points from 81.2% in the same period last year[2] - The net loss for the first nine months of 2024 was CNY 285 million, narrowing by 47.1% compared to the previous year[2] - Total operating revenue for the first three quarters of 2024 reached CNY 697.75 million, a 30% increase from CNY 537.36 million in the same period of 2023[14] - The net loss for the third quarter of 2024 was CNY 285.32 million, compared to a net loss of CNY 539.29 million in the same quarter of 2023, showing an improvement of 47%[16] Cash and Assets - Cash and cash equivalents as of September 30, 2024, amounted to approximately CNY 7.8 billion, providing a solid financial foundation for ongoing projects[4] - Cash and cash equivalents decreased to CNY 6.84 billion from CNY 8.29 billion, a decline of approximately 17.4%[12] - The company’s total assets as of September 30, 2024, were CNY 9.46 billion, a decrease of 4.66% from the end of the previous year[4] - Total cash and cash equivalents at the end of Q3 2024 were 4,949,637,182.02 RMB, down from 5,440,243,367.28 RMB at the end of Q3 2023[18] Research and Development - Research and development expenses for Q3 2024 totaled CNY 194 million, accounting for 69.63% of revenue, a decrease of 48.34 percentage points year-on-year[4] - Research and development expenses accounted for 48.34% of operating revenue in the current reporting period, a decrease of 48.34 percentage points compared to the same period last year, primarily due to a significant increase in operating revenue[7] - Research and development expenses increased to CNY 614.98 million, up from CNY 549.72 million, indicating a growth of 11.9% year-over-year[14] - The company plans to continue focusing on R&D and market expansion strategies to enhance future growth prospects[16] Shareholder Information - The total number of ordinary shareholders as of the reporting period end was 1,762,567,202 shares, with 84.89% listed in Hong Kong[8] - HKSCC NOMINEES LIMITED held 857,691,175 shares, accounting for 48.66% of total shares[9] - HHLR Fund, L.P. and its concerted parties held 208,671,222 shares, representing 11.84% of total shares[9] - King Bridge Investments Limited and its concerted parties held 158,588,612 shares, which is 8.99% of total shares[9] Financial Liabilities and Expenses - The company reported a total liability of CNY 2.64 billion, slightly down from CNY 2.74 billion, indicating a reduction of approximately 3.6%[13] - The company’s equity attributable to shareholders decreased to CNY 6.80 billion from CNY 7.15 billion, a decline of about 5.2%[13] - The company reported a foreign exchange loss of 120.03 million year-to-date, which is an increase compared to the previous year[7] - The company’s financial expenses turned positive, showing a gain of CNY 147.53 million compared to a loss of CNY 35.90 million in the previous year[14] Cash Flow Activities - Net cash flow from operating activities was -333,136,181.63 RMB, an improvement from -446,143,350.48 RMB in the same period last year[17] - Cash inflow from investment activities totaled 4,648,580,477.88 RMB, slightly down from 4,686,238,569.10 RMB in Q3 2023[17] - Cash flow from financing activities resulted in a net outflow of -261,692,786.26 RMB, a decrease from a net inflow of 7,832,072.06 RMB in Q3 2023[18] - The company received 1,065,300,000.00 RMB in cash from borrowings, a significant increase from 27,200,000.00 RMB in the same period last year[18]